Ann: Mesoblast Maintains Momentum with FDA, page-39

Let us not forget the (regular) idiot posters - who allegedly hold MSB - that tried to suggest before this release, that it was not going to eventuate before month end, suggesting Mesoblast management were lying/embellishing to pump the stock price.

I don't know what the markets, ergo investors, want? The first and only proper allogeneic mesenchymal stem cell approval from the FDA, a paradigm changing approval, and a clear FDA accelerated approval pathway for Revascor in the treatment of patients with ischemic chronic heart failure; likely similar forthcoming clear pathway for Ryoncil in adults with SR-aGvHD via an already prepared and funded NIH-funded Bone Marrow Transplant Clinical Trials Network (BMT-CTN) in July; and confirmation of a further 20 transplant Ryconcil centres by the end of the quarter; and 2/3's of USA patients covered, and the remaining 14 of 51 states uncovered at present via Medicaid to online July 1, 2025.

Clearly another progressive confirmatory mkt update, reducing execution risk questions over MSB. Seems like some investors are never happy. I will be one of the many buyers happy to take the other side to your lower priced EOFY tax dodge sells from your poor buying level choices of the 2024/25 tax year in coming days.